FMP
Deciphera Pharmaceuticals, Inc.
DCPH
NASDAQ
Inactive Equity
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
25.59 USD
0.02 (0.07816%)
Historical Prices
From:
To:
About
ceo
Mr. Steven L. Hoerter
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
website
https://www.deciphera.comexchange
NASDAQ
Description
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to ...
CIK
0001654151
ISIN
US24344T1016
CUSIP
24344T101
Address
200 Smith Street
Phone
781 209 6400
Country
US
Employee
355
IPO Date
Sep 28, 2017
Financial Statement
Earnings
DCPH Financial Summary
CIK
0001654151
Exchange
NASDAQ
Industry
Drug Manufacturers -...
Sector
Healthcare
CUSIP
24344T101
ISIN
US24344T1016
Country
US
Price
25.59
Beta
0.18
Volume Avg.
1.86M
Market Cap
2.21B
Shares
-
52-Week
9.9-25.61
DCF
17.21
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-11.58
P/B
-
Website
https://www.deciphera.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest DCPH News
Zacks Investment Research
May 23, 2024
Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why
Deciphera (DCPH) soars 74.3% in the past month on a $2.4 billion buy-out offer from ONO Pharmaceuticals. The transaction is expected to close in the third quarter of 2024.
Zacks Investment Research
May 10, 2024
Here's What Key Metrics Tell Us About Deciphera Pharmaceutic...
While the top- and bottom-line numbers for Deciphera Pharmaceuticals (DCPH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks Investment Research
May 10, 2024
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Miss...
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.60 per share a year ago.
Reuters
Apr 30, 2024
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first s...
Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets.
Invezz
Apr 29, 2024
ONO to buy Deciphera Pharmaceuticals at a huge premium
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) is up a whopping 75% today after ONO Pharmaceutical (TYO: 4528) announced plans of buying it for $2.4 billion. Deciphera Pharmaceuticals stock valued at $25.60 The cash offer values each share of Deciphera Pharmaceuticals at $25.60.
InvestorPlace
Apr 29, 2024
Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?
Deciphera Pharmaceuticals (NASDAQ: DCPH ) stock is rising higher on Monday after signing a $2.4 billion acquisition agreement with ONO Pharmaceutical. This deal has ONO Pharmaceutical acquiring Deciphera Pharmaceuticals for $25.60 per share in cash.
Barrons
Apr 29, 2024
Deciphera Pharmaceuticals Is Being Acquired and the Stock So...
Deciphera Pharmaceuticals is being bought by Japan's ONO Pharmaceutical in a deal valued at $2.4 billion.
Market Watch
Apr 29, 2024
Deciphera to be acquired by Japan's Ono in all-cash deal val...
Deciphera Pharmaceuticals Inc. DCPH, +3.31% said Monday it has agreed to be acquired by Japan's Ono Pharmaceutical Co. Ltd 4528, +1.34% in an all-cash deal valued at $2.4 billion. Under the terms of the deal, Ono will pay $25.60 per Deciphera share through a tender offer after which it will merge the Waltham, Mass.
